Innate Pharma to Participate in European Midcap Event

Innate Pharma SA ( (FR:IPH) ) just unveiled an announcement.

Innate Pharma announced its participation in the 25th European Midcap Event from September 30 to October 1, 2025, in Paris, France. This event is significant for fostering strategic meetings and financing opportunities, potentially impacting Innate Pharma’s industry positioning and stakeholder engagement.

The most recent analyst rating on (FR:IPH) stock is a Hold with a EUR3.10 price target. To see the full list of analyst forecasts on Innate Pharma SA stock, see the FR:IPH Stock Forecast page.

More about Innate Pharma SA

Innate Pharma S.A. is a global, clinical-stage biotechnology company focused on developing immunotherapies for cancer patients. The company leverages its ANKET® platform for NK Cell Engagers, Antibody Drug Conjugates, and monoclonal antibodies, with partnerships with biopharmaceutical giants like Sanofi and AstraZeneca.

YTD Price Performance: -10.72%

Average Trading Volume: 161,519

Technical Sentiment Signal: Strong Sell

Current Market Cap: €158.9M

For a thorough assessment of IPH stock, go to TipRanks’ Stock Analysis page.